Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Yestar Healthcare Holdings Company Limited
巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

FULFILLMENT OF PROFIT GUARANTEE IN RELATION TO THE ACQUISITIONS

Reference is made to the announcements of Yestar Healthcare Holdings Company Limited (the "**Company**") dated 10 April 2015, 13 October 2016, 27 October 2016, 11 November 2016 and 20 September 2017, respectively, in respect of, amongst other things, the acquisition of 70% equity interests in each of the five companies, all are principally engaged in distribution of medical devices including in-vitro diagnostic products.

Pursuant to the respective share transfer agreement for each of the five companies, there is a provision of profit guarantee (the audited consolidated net profit after taxation in accordance with the IFRS) undertaken by the respective vendors of each of the five companies for the year ended 31 December 2017.

The board of directors (the "**Directors**") of the Company is pleased to announce that the 2017 actual net profit after taxation for each of the five companies is more than that of their respective annual guarantee profit undertaken by the respective vendors for the year ended 31 December 2017. As the annual guarantee profit for each of the five companies has been fulfilled, no compensation is required to be paid by the respective vendors for each of the respective five companies pursuant to their respective share transfer agreements. Details of fulfillment of profit guarantee for each of the five companies are as follows:

		For the Year Ended 31 December 2017	
Date of Announcement	**Name of Company**	**Annual Guarantee Profit**	**Actual Net Profit After Taxation**
10 April 2015	Shanghai Emphasis Group Companies (Shanghai Emphasis Investment Management Consulting Co., Ltd., Shanghai Jianchu Medical Instrument Co., Ltd., Shanghai Chaolian Trading Co., Ltd., Shanghai Haole Industrial Co., Ltd. and Shanghai Dingpei Industrial Co., Ltd.)	RMB225.0 million	RMB284.1 million
13 October 2016	Guangzhou Hongen Medical Diagnostic Technologies Company Limited	RMB48.0 million	RMB49.2 million
27 October 2016	Shenzhen De Run Li Jia Company Ltd.	RMB51.0 million	RMB52.8 million
11 November 2016	Guangzhou Shengshiyuan Trading Company Limited	RMB23.8 million	RMB24.4 million
20 September 2017	Beijing Kaihongda Technology Company Limited	RMB15.0 million	RMB15.6 million

By Order of the Board
Yestar Healthcare Holdings Company Limited
巨星醫療控股有限公司
Hartono James
Chairman, CEO and Executive Director

Hong Kong, 15 March 2018

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Ying, Mr. Chan To Keung, Ms. Wang Hong and Mr. Chan Chung Man; and the independent non-executive Directors are Dr. Hu Yiming, Mr. Karsono Tirtamarta (Kwee Yoe Chiang) and Mr. Sutikno Liky.